SEC Comment Letter for Oncocyte Corp (OCX) (CIK 0001642380) (IMDX) — Oct 18, 2017
Oncocyte Corp (OCX) (CIK 0001642380)
Date: Oct. 18, 2017 · CIK: 0001642380 · Accession: 0000000000-17-036988
AI Filing Summary & Sentiment
Letter
October 10, 2017 William Annett President and Chief Executive Officer OncoCyte Corporation 1010 Atlantic Avenue, Suite 102 Alameda, California 94501 OncoCyte Corporation Registration Statement on Form S-3 Filed October 2, 2017 File No. 333-220769Re: Dear Mr. Annett: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Irene Paik at 202-551-6553 with any questions. Division of Corporation Finance cc: Andrew Ledbetter - DLA Piper LLP (US)
Show Raw Text
October 10, 2017 William Annett President and Chief Executive Officer OncoCyte Corporation 1010 Atlantic Avenue, Suite 102 Alameda, California 94501 OncoCyte Corporation Registration Statement on Form S-3 Filed October 2, 2017 File No. 333-220769Re: Dear Mr. Annett: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Irene Paik at 202-551-6553 with any questions. Division of Corporation Finance cc: Andrew Ledbetter - DLA Piper LLP (US)